<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tobramycin (oral inhalation): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tobramycin (oral inhalation): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tobramycin (oral inhalation): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="104959" href="/d/html/104959.html" rel="external">see "Tobramycin (oral inhalation): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="105136" href="/d/html/105136.html" rel="external">see "Tobramycin (oral inhalation): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F45031230"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Bethkis;</li>
<li>Kitabis Pak;</li>
<li>Tobi;</li>
<li>Tobi Podhaler</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872039"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>TEVA-Tobramycin;</li>
<li>Tobi;</li>
<li>Tobi Podhaler</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F45031235"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Aminoglycoside</li></ul></div>
<div class="block doa drugH1Div" id="F45031283"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="df85d498-37b3-4d24-95e1-d4a9ea8cb8c0">Cystic fibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis: </b>
<b>Inhalation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Bethkis, Kitabis Pak, Tobi: 300 mg every 12 hours (do not administer doses &lt;6 hours apart); administer in repeated cycles of 28 days on drug followed by 28 days off drug.</p>
<p style="text-indent:-2em;margin-left:4em;">Tobi Podhaler: 112 mg (4 x 28 mg capsules) every 12 hours (do not administer doses &lt;6 hours apart); administer in repeated cycles of 28 days on drug followed by 28 days off drug.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed</i>
<i> dose:</i> If &lt;6 hours before next scheduled dose, skip the missed dose and resume usual dosing schedule.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8e07ee4b-63ef-4a06-af4a-2fc4fa8fc253">Non–cystic fibrosis bronchiectasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–cystic fibrosis bronchiectasis</b>
<b>(off-label use):</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute exacerbation: </i>
<b>Inhalation for nebulization:</b> 80 mg twice daily in combination with systemic antimicrobial therapy. <b>Note:</b> Efficacy data for treatment are limited and inconclusive (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20500046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20500046'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic suppression: </i>
<b>Inhalation for nebulization:</b> 160 mg or 300 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20627931','lexi-content-ref-35863486']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20627931','lexi-content-ref-35863486'])">Ref</a></span>). <b>Note:</b> Reserve use for patients with ≥3 exacerbations requiring antibiotic therapy per year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20627931','lexi-content-ref-28889110']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20627931','lexi-content-ref-28889110'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58f09831-e1d9-4d13-a555-4196b8a7ce81">Pneumonia, hospital-acquired or ventilator-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-acquired or ventilator-associated (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Inhalation for nebulization:</b> 300 mg every 12 hours in combination with IV antimicrobial therapy. <b>Note:</b> Efficacy is uncertain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31974920']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31974920'])">Ref</a></span>); some experts reserve for patients with risk for multidrug-resistant pathogens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Klompas.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Klompas.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991686"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989009"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, does not undergo hepatic metabolism.</p></div>
<div class="block dop drugH1Div" id="F45031282"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="105136" href="/d/html/105136.html" rel="external">see "Tobramycin (oral inhalation): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3ca01a17-873d-4de0-b25e-586b91d1d836">Eradication of new or initial <i>Pseudomonas aeruginosa</i> airway culture in patients with cystic fibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Eradication of new or initial <i>Pseudomonas aeruginosa </i>airway culture in patients with cystic fibrosis:</b> Limited data available: Infants ≥6 months, Children, and Adolescents: Inhalation: 300 mg every 12 hours for 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25549030','lexi-content-ref-12480612','lexi-content-ref-29685813']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25549030','lexi-content-ref-12480612','lexi-content-ref-29685813'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d9753ae0-8afa-4f4d-9059-376adb6f2044">
<i>Pseudomonas aeruginosa</i> colonization; chronic lung maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Pseudomonas aeruginosa</i> colonization; chronic lung maintenance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients with cystic fibrosis:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Bethkis, Kitabis Pak, Tobi: Children and Adolescents (limited data in children &lt;6 years): Inhalation: 300 mg every 12 hours; administer in repeated cycles of 28 days on drug followed by 28 days off drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21893650','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21893650','lexi-content-ref-Manu.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Tobi Podhaler: Children ≥6 years and Adolescents: Inhalation: 112 mg (4 x 28 mg capsules) every 12 hours; administer in repeated cycles of 28 days on drug followed by 28 days off drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients without cystic fibrosis:</i> Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Doses are from initial studies of patients with cystic fibrosis (CF) using the IV product as inhalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2505216','lexi-content-ref-2494640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2505216','lexi-content-ref-2494640'])">Ref</a></span>). Some centers utilize this dose in patients without CF for treatment of pulmonary disease (eg, bronchiectasis, tracheitis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18518833']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18518833'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Inhalation: 80 mg/dose 2 to 3 times daily.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51192873"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51192874"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F45031251"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Central nervous system: Voice disorder (4% to 14%), headache (11% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;">Respiratory: Cough (powder: 10% to 48%, solution: 31%), rhinitis (solution: 11% to 35%), pulmonary disease (30% to 34%; includes pulmonary or cystic fibrosis exacerbations), reduced forced expiratory volume (solution: 1% to 31%, powder: 4%), discoloration of sputum (21%), productive cough (18% to 20%), rales (solution: 6% to 19%, powder: 7%), dyspnea (12% to 16%), decreased lung function (7% to 16%), oropharyngeal pain (11% to 14%), hemoptysis (12% to 13%), pharyngolaryngeal pain (powder: 11%, solution: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;">Miscellaneous: Fever (12% to 16%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardiovascular: Chest discomfort (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Central nervous system: Malaise (6%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dermatologic: Skin rash (2%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Endocrine: Increased serum glucose (powder: 3%, solution: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrointestinal: Nausea (8% to 10%), dysgeusia (powder: 4% to 7%, solution: &lt;1%), vomiting (6%), diarrhea (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hematologic &amp; oncologic: Increased erythrocyte sedimentation rate (solution: 8%), eosinophilia (solution: 2%), increased serum immunoglobulins (solution: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neuromuscular &amp; skeletal: Musculoskeletal chest pain (&lt;1% to 5%), myalgia (solution: ≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Otic: Hypoacusis (powder: 10%), tinnitus (2% to 3%), deafness (≤1%; including unilateral deafness, reported as mild to moderate hearing loss or increased hearing loss)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Respiratory: Upper respiratory tract infection (7% to 9%), nasal congestion (7% to 8%), wheezing (5% to 7%), throat irritation (2% to 5%), bronchospasm (≤1% to 5%), laryngitis (solution: ≤5%) bronchitis (solution: 3%), epistaxis (2% to 3%), tonsillitis (solution: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&lt;1%, postmarketing, and/or case reports: Aphonia, decreased appetite, hypersensitivity reaction, increased bronchial secretions, pneumonitis, pruritus, pulmonary congestion, urticaria</p></div>
<div class="block coi drugH1Div" id="F45031248"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to tobramycin, other aminoglycosides, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F45031249"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchospasm: Bronchospasm may occur; bronchospasm or wheezing should be treated appropriately if either arise.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: Nephrotoxicity was not observed during tobramycin inhalation clinical studies, but has been associated with aminoglycosides. Patients with known or suspected renal dysfunction or taking concomitant nephrotoxic drugs should be closely monitored (renal function tests and serum tobramycin concentrations) as clinically indicated. If nephrotoxicity occurs, discontinue therapy until serum concentrations fall below 2 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis and Parkinson disease; neuromuscular blockade, respiratory failure, and prolonged respiratory paralysis may occur. Concomitant neuromuscular blocking agents may also increase risk for prolonged respiratory paralysis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ototoxicity: Ototoxicity, as measured by complaints of hearing loss or tinnitus, has been reported. Tinnitus may be a sentinel symptom of ototoxicity, and therefore, the onset of this symptom warrants further investigation. Ototoxicity, manifested as both auditory and vestibular toxicity, has been reported with parenteral aminoglycosides. Vestibular toxicity may be manifested by vertigo, ataxia, or dizziness. Patients with known or suspected auditory or vestibular dysfunction should be closely monitored (audiometric evaluations and serum tobramycin concentrations). Baseline audiogram should be considered for patients at increased risk of auditory dysfunction. Use with caution in patients with preexisting vertigo, tinnitus, or hearing loss.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with genomic variants in <i>MT-RNR1</i>: Carriers of certain variants in the <i>MT-RNR1</i> gene (eg, m.1555A&gt;G) may be at increased risk for aminoglycoside-induced ototoxicity, including potentially significant hearing loss that may be irreversible, even when serum levels are within the normal range.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878807"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">With use of Tobi Podhaler (oral capsule powder for inhalation), taste disturbance (dysgeusia) was reported more frequently in pediatric patients ≥6 years (7.4%) than adults (2.7%).</p></div>
<div class="block foc drugH1Div" id="F45031304"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tobi Podhaler: 28 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Nebulization Solution, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg/5 mL (5 mL); 300 mg/4 mL (4 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Nebulization Solution, Inhalation [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bethkis: 300 mg/4 mL (4 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kitabis Pak: 300 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tobi: 300 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg/5 mL (5 mL); 300 mg/4 mL (4 mL)</p></div>
<div class="block geq drugH1Div" id="F45031233"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F45031308"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Tobi Podhaler Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">28 mg (per each): $60.95</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Nebulization</b> (Bethkis Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/4 mL (per mL): $33.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Nebulization</b> (Kitabis Pak Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/5 mL (per mL): $19.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Nebulization</b> (Tobi Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/5 mL (per mL): $35.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Nebulization</b> (Tobramycin Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/4 mL (per mL): $31.15 - $31.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/5 mL (per mL): $8.06 - $28.27</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872040"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tobi Podhaler: 28 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Nebulization Solution, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tobi: 300 mg/5 mL (5 mL) [contains sodium chloride, sodium hydroxide, sulfuric acid]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg/5 mL (5 mL)</p></div>
<div class="block adm drugH1Div" id="F45031289"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Inhalation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Bethkis, Kitabis Pak, Tobi: To be orally inhaled over ~15 minutes using a handheld reusable nebulizer (PARI-LC PLUS) with a PARI Vios air compressor (Bethkis) or a DeVilbiss Pulmo-Aide air compressor (Kitabis Pak, Tobi). If multiple different nebulizer treatments are required, administer bronchodilator first, followed by chest physiotherapy, any other nebulized medications, and then tobramycin last. Do not mix with other nebulizer medications.</p>
<p style="text-indent:-2em;margin-left:4em;">Tobi Podhaler: Capsules should be administered by oral inhalation via Podhaler device following manufacturer recommendations for use and handling. Capsules should be removed from the blister packaging immediately prior to use and should not be swallowed. Patients requiring bronchodilator therapy should administer the bronchodilator 15 to 90 minutes prior to Tobi Podhaler. The sequence of chest physiotherapy and additional inhaled therapies is at the discretion of the healthcare provider; however, Tobi Podhaler should always be administered last.</p>
<p style="text-indent:-2em;margin-left:4em;">Nebulization of injection formulation (off-label route): To prepare tobramycin injection solution for inhalation via nebulizer, further dilute 2 mL of tobramycin 40 mg/mL solution with 2 mL NS for an 80 mg dose (final volume: 4 mL) or 4 mL of tobramycin 40 mg/mL with 4 mL NS for a 160 mg dose (final volume: 8 mL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20627931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20627931'])">Ref</a></span>). Preservative-free injection formulations may be preferred to minimize adverse reactions (eg, bronchoconstriction, cough). Use with jet nebulizer; refer to nebulizer manufacturer's information for usage instructions and volume specifications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20500046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20500046'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52614624"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Inhalation: Doses should be administered as close to prescribed schedule as possible; do not administer &lt;6 hours apart. The Cystic Fibrosis Foundation recommends the following order for patients receiving multiple inhaled medications (as appropriate): Bronchodilator, hypertonic saline, dornase alfa, airway clearance, then inhaled tobramycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23540878']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23540878'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Bethkis, Kitabis Pak, Tobi: Use a PARI LC Plus reusable nebulizer and a PARI Vios air compressor (Bethkis) or a DeVilbiss Pulmo-Aide air compressor (Kitabis Pak, Tobi) for administration; patient should be sitting or standing upright and breathing normally through the mouthpiece of the nebulizer. Nebulizer treatment period is usually over 15 minutes. Do not mix with other nebulizer medications.</p>
<p style="text-indent:-2em;margin-left:2em;">Tobi Podhaler: Capsules should be administered by oral inhalation via Podhaler device following manufacturer recommendations for use and handling. Capsules should be removed from the blister packaging immediately prior to use and should not be swallowed. Patients requiring bronchodilator therapy should administer the bronchodilator 15 to 90 minutes prior to Tobi Podhaler. Use the new Podhaler device provided with each weekly pack.</p></div>
<div class="block use drugH1Div" id="F45031239"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis: </b>Management of cystic fibrosis in adults and pediatric patients ≥6 years of age with <i>Pseudomonas aeruginosa</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Safety and efficacy have not been demonstrated in patients with FEV<sub>1</sub> &lt;40% or &gt;80% predicted (Bethkis) or FEV<sub>1</sub> &lt;25% or &gt;80% predicted (TOBI Podhaler) or FEV<sub>1</sub> &lt;25% or &gt;75% predicted (Kitabis Pak; TOBI), or in patients colonized with <i>Burkholderia cepacia.</i></p></div>
<div class="block off-label drugH1Div" id="F45031240"><span class="drugH1">Use: Off-Label: Adult</span><p>Non–cystic fibrosis bronchiectasis; Pneumonia, hospital-acquired or ventilator-associated</p></div>
<div class="block mst drugH1Div" id="F45031224"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tobramycin may be confused with Trobicin, vancomycin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F45031258"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F45031255"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the nephrotoxic effect of Tobramycin (Oral Inhalation). Loop Diuretics may enhance the ototoxic effect of Tobramycin (Oral Inhalation).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mannitol (Systemic): May enhance the nephrotoxic effect of Tobramycin (Oral Inhalation).<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F45031245"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Aminoglycosides may cause fetal harm if administered to a pregnant woman. Systemic absorption of tobramycin following oral inhalation is expected to be low compared to intravenous administration; however, systemic exposure was associated with total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Tobramycin inhalation may be used for the management of cystic fibrosis in pregnant patients with <i>Pseudomonas aeruginosa</i> (Edenborough 2008).</p></div>
<div class="block brc drugH1Div" id="F45031246"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if tobramycin is present in breast milk following oral inhalation.</p>
<p style="text-indent:-2em;margin-left:2em;">Tobramycin is present in breast milk following injection (Festini 2006; Uwaydah 1975). Systemic absorption following oral inhalation is expected to be low compared to IV administration.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Based on low serum concentrations and low absorption, breastfeeding is considered compatible in women using inhaled tobramycin for the management of cystic fibrosis (Edenborough 2008; Panchaud 2016). Infants should be monitored for loose or bloody stools and candidiasis.</p></div>
<div class="block mop drugH1Div" id="F45031293"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline">The utility of monitoring serum concentrations in patients with renal impairment should be per health care provider discretion; serum concentrations achieved following inhalation are significantly less than those achieved following parenteral therapy in patients with normal renal function. Monitor serum tobramycin concentrations in patients with known or history of auditory dysfunction, renal dysfunction, and/or concomitant use of nephrotoxic drugs. One hour after inhalation, serum concentrations of 1 to 2 mcg/mL have been observed.</p></div>
<div class="block rer drugH1Div" id="F45031269"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Inhalation: Serum concentrations are ~1 to 2 mcg/mL 1 hour following a dose in patients with normal renal function. Routine monitoring of serum concentrations is not required.</p></div>
<div class="block pha drugH1Div" id="F45031267"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Interferes with bacterial protein synthesis by binding to 30S ribosomal subunit, resulting in a defective bacterial cell membrane</p></div>
<div class="block phk drugH1Div" id="F45031270"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Inhalation: Peak serum concentrations:</p>
<p style="text-indent:-2em;margin-left:4em;">Solution for inhalation: ~1 mcg/mL following a 300 mg dose</p>
<p style="text-indent:-2em;margin-left:4em;">Powder for inhalation: ~1 mcg/mL (range: 0.49 to 1.55 mcg/mL) following a 112 mg dose</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Powder for inhalation: V<sub>d</sub> (central compartment) for a typical cystic fibrosis patient: 85.1 L</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Solution for inhalation: ~4.4 hours (Bethkis); ~3 hours (TOBI)</p>
<p style="text-indent:-2em;margin-left:4em;">Powder for inhalation: ~3 hours (after a single 112 mg dose)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Powder for inhalation: 60 minutes</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45650000"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler | Tobradosa | Tobrahaler</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Tobi</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Zoteon</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Zoteon</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Tobi</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Tobi | Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Zoteon</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Tobi | Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Tobi</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Tobi | Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Tobamist | Tobaresp</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Tobi | Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Eppafiq iso | Tobi | Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Tobi</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Tobi | Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bramitop</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Tobradosa</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Tobi Podhaler</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Tobi podhaler</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Tobi</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Zoteon</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-18576909">
<a name="18576909"></a>Abdulhamid I, Wise TL, Andrews S, et al. Elevated Serum Tobramycin Concentrations After Treatment With Tobramycin Inhalation in a Preterm Infant. <i>Pharmacotherapy</i>. 2008;28(7):939-944.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/18576909/pubmed" id="18576909" target="_blank">18576909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bethkis.1">
<a name="Bethkis.1"></a>Bethkis (tobramycin) [prescribing information]. Woodstock, IL: Chiesi USA Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1869596">
<a name="1869596"></a>Bourget P, Fernandez H, Delouis C, et al. Pharmacokinetics of Tobramycin in Pregnant Women. Safety and Efficacy of a Once-Daily Dose Regimen. <i>J Clin Pharm Ther</i>. 1991;16(3):167-176.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/1869596/pubmed" id="1869596" target="_blank">1869596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12431134">
<a name="12431134"></a>Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/12431134/pubmed" id="12431134" target="_blank">12431134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18024241">
<a name="18024241"></a>Edenborough FP, Borgo G, Knoop C, et al. Guidelines for the management of pregnancy in women with cystic fibrosis. <i>J Cyst Fibros</i>. 2008;7(suppl 1):S2-S32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/18024241/pubmed" id="18024241" target="_blank">18024241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16801316">
<a name="16801316"></a>Festini F, Ciuti R, Taccetti G, et al. Breast-Feeding in a Woman With Cystic Fibrosis Undergoing Antibiotic Intravenous Treatment. <i>J Matern Fetal Neonatal Med</i>. 2006;19(6):375-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/16801316/pubmed" id="16801316" target="_blank">16801316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12480612">
<a name="12480612"></a>Gibson RL, Emerson J, McNamara S, et al; Cystic Fibrosis Therapeutics Development Network Study Group. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.<i> Am J Respir Crit Care Med</i>. 2003;167(6):841-849. doi:10.1164/rccm.200208-855OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/12480612/pubmed" id="12480612" target="_blank">12480612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35863486">
<a name="35863486"></a>Guan WJ, Xu JF, Luo H,et al; TORNASOL study group. A double-blind randomized placebo-controlled phase 3 trial of tobramycin inhalation solution in adults with bronchiectasis with pseudomonas aeruginosa infection. <i>Chest</i>. 2023;163(1):64-76. doi:10.1016/j.chest.2022.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/35863486/pubmed" id="35863486" target="_blank">35863486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12680485">
<a name="12680485"></a>Kahler DA, Schowengerdt KO, Fricker FJ, et al. Toxic Serum Trough Concentrations After Administration of Nebulized Tobramycin. <i>Pharmacotherapy</i>. 2003;23(4):543-545.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/12680485/pubmed" id="12680485" target="_blank">12680485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kitabis.1">
<a name="Kitabis.1"></a>Kitabis Pak (tobramycin inhalation solution) [prescribing information]. Woodstock, IL: Catalent Pharma Solutions LLC; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Klompas.1">
<a name="Klompas.1"></a>Klompas M. Treatment of hospital-acquired and ventilator-associated pneumonia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 2, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31405826">
<a name="31405826"></a>Laska IF, Crichton ML, Shoemark A, Chalmers JD. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. <i>Lancet Respir Med</i>. 2019;7(10):855-869. doi:10.1016/S2213-2600(19)30185-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/31405826/pubmed" id="31405826" target="_blank">31405826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20500046">
<a name="20500046"></a>Le J, Ashley ED, Neuhauser MM, et al; Society of Infectious Diseases Pharmacists Aerosolized Antimicrobials Task Force. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i>. 2010;30(6):562-584.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/20500046/pubmed" id="20500046" target="_blank">20500046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2505216">
<a name="2505216"></a>
<b></b> MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. <i>Pediatr Pulmonol</i>. 1989;7(1):42-48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/2505216/pubmed" id="2505216" target="_blank">2505216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23540878">
<a name="23540878"></a>Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. <i>Am J Respir Crit Care Med</i>. 2013;187(7):680-689.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/23540878/pubmed" id="23540878" target="_blank">23540878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25549030">
<a name="25549030"></a>Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic Fibrosis Foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. <i>Ann Am Thorac Soc</i>. 2014;11(10):1640-1650.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/25549030/pubmed" id="25549030" target="_blank">25549030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26942733">
<a name="26942733"></a>Panchaud A, Di Paolo ER, Koutsokera A, et al. Safety of drugs during pregnancy and breastfeeding in cystic fibrosis patients. <i>Respiration</i>. 2016;91(4):333-348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/26942733/pubmed" id="26942733" target="_blank">26942733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20627931">
<a name="20627931"></a>Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis Non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. <i>Thorax</i>. 2010;65(suppl 1):i1-i58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/20627931/pubmed" id="20627931" target="_blank">20627931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28889110">
<a name="28889110"></a>Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. <i>Eur Respir J</i>. 2017;50(3):1700629. doi:10.1183/13993003.00629-2017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/28889110/pubmed" id="28889110" target="_blank">28889110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ramsey.1">
<a name="Ramsey.1"></a>Ramsey BW, Burns J, Smith A, et al. Safety and Efficacy of Tobramycin for Inhalation in Patients With Cystic Fibrosis: The Results of Two Phase III Placebo Controlled Clinical Trials. <i>Pediatr Pulmonol</i>. 1997(suppl 14):137-138, S10.3.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8497284">
<a name="8497284"></a>Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of Aerosolized Tobramycin in Patients With Cystic Fibrosis. <i>N Engl J Med</i>. 1993;328(24):1740-1746.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/8497284/pubmed" id="8497284" target="_blank">8497284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9878641">
<a name="9878641"></a>Ramsey BW, Pepe MS, Quan JM, et al. Intermittent Administration of Inhaled Tobramycin in Patients With Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. <i>N Engl J Med</i>. 1999;340(1):23-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/9878641/pubmed" id="9878641" target="_blank">9878641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29685813">
<a name="29685813"></a>Ratjen F, Moeller A, McKinney ML, et al. Eradication of early P. aeruginosa infection in children &lt;7 years of age with cystic fibrosis: the early study. <i>J Cyst Fibros</i>. 2019;18(1):78-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/29685813/pubmed" id="29685813" target="_blank">29685813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15795653">
<a name="15795653"></a>Redmann S, Wainwright C, Stacey S, et al. Misleading High Tobramycin Plasma Concentrations Can Be Caused by Skin Contamination of Fingerprick Blood Following Inhalation of Nebulized Tobramycin (TOBI): A Short Report. <i>Ther Drug Monit</i>. 2005;27(2):205-207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/15795653/pubmed" id="15795653" target="_blank">15795653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18518833">
<a name="18518833"></a>Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. <i>J Aerosol Med Pulm Drug Deliv</i>. 2008;21(1):71-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/18518833/pubmed" id="18518833" target="_blank">18518833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shaw.1">
<a name="Shaw.1"></a>Shaw PK, Braun TL, Liebergen A, et al. Aerosolized Tobramycin Pharmacokinetics in Cystic Fibrosis Patients. <i>J Pediatr Pharm Pract</i>. 1997;2(1):23-26.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2494640">
<a name="2494640"></a>Steinkamp G, Tümmler B, Gappa M, et al. Long-term tobramycin aerosol therapy in cystic fibrosis. <i>Pediatr Pulmonol</i>. 1989;6(2):91-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/2494640/pubmed" id="2494640" target="_blank">2494640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31974920">
<a name="31974920"></a>Stokker J, Karami M, Hoek R, Gommers D, van der Eerden M. Effect of adjunctive tobramycin inhalation versus placebo on early clinical response in the treatment of ventilator-associated pneumonia: the VAPORISE randomized-controlled trial. <i>Intensive Care Med</i>. 2020;46(3):546-548. doi:10.1007/s00134-019-05914-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/31974920/pubmed" id="31974920" target="_blank">31974920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tobi.1">
<a name="Tobi.1"></a>Tobi (tobramycin) [prescribing information]. Morgantown, WV: Mylan Specialty LP; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TobiPodhaler.1">
<a name="TobiPodhaler.1"></a>Tobi Podhaler (tobramycin) [prescribing information]. Morgantown, WV: Mylan Specialty LP; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21893650">
<a name="21893650"></a>Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al; Early Pseudomonas Infection Control (EPIC) Investigators. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. <i>Arch Pediatr Adolesc Med</i>. 2011;165(9):847-856. doi:10.1001/archpediatrics.2011.136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/21893650/pubmed" id="21893650" target="_blank">21893650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1107297">
<a name="1107297"></a>Uwaydah M, Bibi S, Salman S. Therapeutic Efficacy of Tobramycin - A Clinical and Laboratory Evaluation. <i>J Antimicrob Chemother</i>. 1975;1(4):429-437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/1107297/pubmed" id="1107297" target="_blank">1107297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30442203">
<a name="30442203"></a>Xu F, He LL, Che LQ, et al. Aerosolized antibiotics for ventilator-associated pneumonia: a pairwise and Bayesian network meta-analysis. <i>Crit Care</i>. 2018;22(1):301. doi:10.1186/s13054-018-2106-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-oral-inhalation-drug-information/abstract-text/30442203/pubmed" id="30442203" target="_blank">30442203</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 104956 Version 227.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
